Neuraxis (NRXS) Stock Price

Neuraxis Price

NYSE·CLOSED
4.50
​
Market closed

Over the last 5 years Neuraxis grew revenue by 13.1% annually, reaching 3.57 M USD. For Neuraxis, the net margin of -218.5% is down versus -111.3% a few years ago. The consensus 12-month price target for Neuraxis is 7.14 USD, about 58.7% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Neuraxis stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis business model & stock analysis

NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market.

Frequently asked questions about Neuraxis

Analysts currently set an average price target of 7.14 USD for the Neuraxis stock (median: 7.14 USD), implying +69.2 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Neuraxis stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuraxis to generate revenue of 7.80 M USD and earnings per share of -0.95 USD.

Converted at the current exchange rate, the Neuraxis share trades at 4.10 EUR (4.50 USD).

The expected revenue of Neuraxis is 7.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Neuraxis is -8.63 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neuraxis is currently -4.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuraxis stock.

The price-to-sales ratio (P/S) of Neuraxis is currently 5.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuraxis stock.

The Eulerpool Quality Score for Neuraxis is 5/10.

The ISIN of Neuraxis is US64134X2018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Neuraxis is NRXS. The ticker symbol is used to trade Neuraxis shares on the stock exchange.

Fair ValueTerminal
4.41 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
209,957.76 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website neuraxis.com
Currency
USD
Initial public offering
Aug 9, 2023
ISIN
US64134X2018
Cusip
64134X201
Market capitalization
47.93 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-4.74
P/Ee 2027
-6.85
P/Ee 2028
450.00
P/Se
5.24
EV/EBIT
—
P/B Ratio
14.10
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-204.42 %
Last updated Nov 22, 2026, 3:45 AM

Neuraxis Peer Group

Neuraxis FIGI

NRXS:US · BBG01C9N12C3NRXS:UA · BBG01C9N12D2NRXS:UC · BBG01C9N12F0NRXS:UN · BBG01C9N12H8NRXS:UP · BBG01C9N12J6NRXS:UB · BBG01C9N12L3NRXS:UT · BBG01C9N12M2NRXS:UM · BBG01C9N12N1NRXS:UX · BBG01C9N12P9NRXS:UD · BBG01C9N12V2NRXS:UF · BBG01C9N12Y9NRXS:VY · BBG01C9N12Z8

All fundamentals and in-depth analysis of Neuraxis

Our stock analysis for Neuraxis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuraxis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.